Pfeffer, Marc A.

Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure

Solomon, S. D., Dobson, J., Pocock, S., Skali, H., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Young, J. B., Michelson, E. L., et al. (2007) · Circulation

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 681

AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update: A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology

Smith, S. C., Blair, S. N., Bonow, R. O., Brass, L. M., Cerqueira, M. D., Dracup, K., Fuster, V., Gotto, A., Grundy, S. M., Miller, N. H., et al. (2001) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 661

Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction

Olsson, L. G., Swedberg, K., Ducharme, A., Granger, C. B., Michelson, E. L., McMurray, J. J. V., Puu, M., Yusuf, S., & Pfeffer, M. A. (2006) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 574

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 490

Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone

Shah, A. M., Claggett, B., Sweitzer, N. K., Shah, S. J., Anand, I. S., Liu, L., Pitt, B., Pfeffer, M. A., & Solomon, S. D. (2015) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 478

Reduction of Stroke Incidence After Myocardial Infarction With Pravastatin: The Cholesterol and Recurrent Events (CARE) Study

Plehn, J. F., Davis, B. R., Sacks, F. M., Rouleau, J. L., Pfeffer, M. A., Bernstein, V., Cuddy, T. E., Moyé, L. A., Piller, L. B., Rutherford, J., et al. (1999) · Circulation

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 429

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease

Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M., et al. (2007) · Circulation

Lipoproteins and Cardiovascular HealthInflammatory Biomarkers in Disease Prognosis

Cited by 385

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Ducharme, A., Swedberg, K., Pfeffer, M. A., Cohen-Solal, A., Granger, C. B., Maggioni, A. P., Michelson, E. L., McMurray, J. J. V., Olsson, L., Rouleau, J. L., et al. (2006) · American Heart Journal

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 352

Longitudinal and Circumferential Strain Rate, Left Ventricular Remodeling, and Prognosis After Myocardial Infarction

Hung, C.-L., Verma, A., Uno, H., Shin, S.-H., Bourgoun, M., Hassanein, A. H., McMurray, J. J., Velazquez, E. J., Kober, L., Pfeffer, M. A., et al. (2010) · Journal of the American College of Cardiology

Cardiovascular Function and Risk FactorsCardiac Imaging and Diagnostics

Cited by 305

Additive Beneficial Effects of Beta-Blockers to Angiotensin-Converting Enzyme Inhibitors in the Survival and Ventricular Enlargement (SAVE) Study fn1fn1This study was supported by a University-Industry grant from the Medical Research Council, Ottawa, Ontario, Canada and Bristol Myers Squibb, Montreal, Quebec, Canada.

Vantrimpont, P., Rouleau, J. L., Wun, C.-C., Ciampi, A., Klein, M., Sussex, B., Arnold, J. M. O., Moyé, L., & Pfeffer, M. (1997) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementAcute Myocardial Infarction Research

Cited by 274

Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved

Rogers, J. K., Pocock, S. J., McMurray, J. J. V., Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K., & Yusuf, S. (2014) · European Journal of Heart Failure

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 226

Incidence and Predictors of Hyperkalemia in Patients With Heart Failure

Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., et al. (2007) · Journal of the American College of Cardiology

Potassium and Related DisordersHeart Failure Treatment and Management

Cited by 170

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

Effect of pravastatin in people with diabetes and chronic kidney disease

Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 159

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

Jackson, A. M., Jhund, P. S., Anand, I. S., Düngen, H.-D., Lam, C. S. P., Lefkowitz, M. P., Linssen, G., Lund, L. H., Maggioni, A. P., Pfeffer, M. A., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 156

Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction

Bello, N. A., Claggett, B., Desai, A. S., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., & Solomon, S. D. (2014) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 147

Comparison of time-to-first event and recurrent-event methods in randomized clinical trials

Claggett, B., Pocock, S., Wei, L. J., Pfeffer, M. A., McMurray, J. J. V., & Solomon, S. D. (2018) · Circulation

Statistical Methods in Clinical TrialsStatistical Methods and Bayesian Inference

Cited by 118

Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

Lewis, E. F., Kim, H.-Y., Claggett, B., Spertus, J., Heitner, J. F., Assmann, S. F., Kenwood, C. T., Solomon, S. D., Desai, A. S., Fang, J. C., et al. (2016) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 114

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes

CHARM Investigators and Committees, Kristensen, S. L., Jhund, P. S., Lee, M. M. Y., Køber, L., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K., et al. (2017) · Cardiovascular Drugs and Therapy

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 83

Prognosis and Response to Therapy of First Inpatient and Outpatient Heart Failure Event in a Heart Failure Clinical Trial: MADIT-CRT

Skali, H., Dwyer, E. M., Goldstein, R., Haigney, M., Krone, R., Kukin, M., Lichstein, E., McNitt, S., Moss, A. J., Pfeffer, M. A., et al. (2014) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiac pacing and defibrillation studies

Cited by 76

Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program

Preiss, D., Zetterstrand, S., McMurray, J. J. V., Östergren, J., Michelson, E. L., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., Gerstein, H. C., et al. (2009) · Diabetes Care

Heart Failure Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 76

Worsening Renal Function and Outcome in Heart Failure Patients with Reduced and Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment: Data from the CHARM-Study Programme

Damman, K., Solomon, S. D., Pfeffer, M. A., Swedberg, K., Yusuf, S., Young, J. B., Rouleau, J. L., Granger, C. B., & McMurray, J. J. V. (2016) · European Journal of Heart Failure

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 75

Health‐related quality of life outcomes in PARAGON‐HF

Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., et al. (2022) · European Journal of Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 33

Myocardial Infarction in Heart Failure With Preserved Ejection Fraction

Cunningham, J. W., Vaduganathan, M., Claggett, B. L., John, J. E., Desai, A. S., Lewis, E. F., Zile, M. R., Carson, P., Jhund, P. S., Kober, L., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 33